8-K: Wellgistics Health Promotes Brian Norton to CEO, Expands Healthcare Ecosystem

Wellgistics Health, Inc. announces the promotion of Brian Norton to CEO and a collaboration with Protega Pharmaceuticals to support pharmacist education and patient access to abuse-deterrent opioid ROXYBOND.

Summary

• Wellgistics Health, Inc. has appointed Brian Norton as its new Chief Executive Officer, effective February 28, 2025.
• Norton previously served as CEO of Wellgistics LLC, a subsidiary, and Chief Commercial Officer and President of Distribution for Wellgistics Health, Inc.
• His annual base salary will be $490,000, with potential increases and bonuses based on performance metrics.
• He will also receive a $1,000 monthly automobile allowance and a $15,000 relocation allowance.
• Norton will be granted 9,000,000 Restricted Stock Units (RSUs) that vest over three years, contingent on the company meeting certain revenue and profit targets.
• Timothy Canning, the previous CEO, resigned effective the same date, with no disputes cited as the reason.
• Wellgistics Health is also collaborating with Protega Pharmaceuticals to support pharmacist education and increase patient access to ROXYBOND, an abuse-deterrent immediate-release opioid.
• The collaboration aims to educate pharmacists on responsible pain management and regulatory compliance.
• Wellgistics LLC will distribute ROXYBOND to independent pharmacies across 50 states, particularly in underserved areas.
• A press release was issued on March 4, 2025, announcing the collaboration with Protega Pharmaceuticals Inc.
• A revised investor presentation was posted on the company's website on March 4, 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments (new CEO, collaboration) and potential risks (opioid-related issues, forward-looking statements). The overall sentiment is cautiously optimistic.

Positives

• Brian Norton's promotion to CEO brings his experience and track record in the healthcare sector to the company's leadership.
• The collaboration with Protega Pharmaceuticals aligns with Wellgistics Health's mission to improve patient lives and deliver unique solutions for pharmacies and manufacturers.
• The focus on pharmacist education and responsible opioid dispensing can help mitigate risks associated with opioid misuse and diversion.
• The availability of ROXYBOND in multiple dosages can enhance flexibility and precision in opioid therapy for patients.
• The company is expanding its healthcare ecosystem with Protega Pharmaceuticals Inc.

Negatives

• The document mentions that the Company is in default under its credit facility with Zions Bank.
• The document mentions that the Company has not received any notice that it is in conflict with or infringing upon the asserted intellectual property rights of others in connection with the Company Intellectual Property, and, to the Knowledge of the Company, neither the Company's use of the Company Intellectual Property nor the operation of the Company's business is infringing, has infringed upon, is violating, has violated or misappropriated any intellectual property rights of any Person;.
• The document mentions that the Company has not received any notice that it is in conflict with or infringing upon the asserted intellectual property rights of others in connection with the Licensed Intellectual Property, and, to the Knowledge of the Company, neither the Company's use of the Licensed Intellectual Property nor the operation of the Company's business is infringing or has infringed upon any intellectual property rights of others;.
• The document mentions that the Company has not received any notice that any customer or supplier has cancelled, terminated or otherwise altered (including any reduction in the rate or amount of sales or purchases, increases in the prices charged or paid, or change to the supply or credit terms, as the case may be) or notified the Company of any intention to do any of the foregoing or otherwise threatened to cancel, terminate or alter (including any reduction in the rate or amount of sales or purchases, in the prices charged or paid, or change to the supply or credit terms, as the case may be) its relationship with the Company.
• The document mentions that the Company has no pending or, to the Knowledge of the Company, threatened investigations by any branch or department of U.S. Immigration and Customs Enforcement (ICE), or other federal agency charged with administration and enforcement of federal immigration laws concerning the Company.
• The document mentions that the Company has not had any unauthorized access, disclosure, maintenance or use of personal data, or successful Security Incident or Breach of Unsecured PHI (as those terms are defined under HIPAA) (together, a Security Event), that is or was required to be reported to individuals, a governmental agency or media or required to be reported under any other Data Privacy and Security Law.
• The document mentions that the Company is not in breach or default of any obligation owed to any creditor for borrowed money or any other creditor who may have a Lien on any of its rights and assets.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties, which may cause actual results to differ materially from expectations.
• The company's success depends on market conditions and other factors discussed in the Risk Factors section of filings with the SEC.
• The company is subject to the risks of addiction, abuse, and misuse with opioids, which can occur any dosage or duration.
• The company is subject to the risk of life-threatening respiratory depression, which may occur with use of ROXYBOND, especially during initiation or following a dosage increase.
• The company is subject to the risk of accidental ingestion of even one dose of ROXYBOND, especially by children, which can result in a fatal overdose of oxycodone.
• The company is subject to the risks from concomitant use with benzodiazepines or other CNS depressants, which may result in profound sedation, respiratory depression, coma, and death.
• The company is subject to the risk of neonatal opioid withdrawal syndrome (NOWS), which may be life-threatening if not recognized and treated.
• The company is subject to the risk of cytochrome P450 3A4 interaction, which may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression.

Future Outlook

The company intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from specialty-lite to general maintenance conditions.

Management Comments

• Paul Howe, Chief Commercial Officer of Protega, stated that the collaboration aligns with their mission to make the opioid market safer and supports a controlled, compliant, and responsible distribution network.
• Brian Norton, Chief Executive Officer of Wellgistics Health, Inc., emphasized the company's commitment to regulatory integrity and patient safety, ensuring independent pharmacies have the tools, education, and access they need to dispense medications responsibly.

Industry Context

The collaboration between Wellgistics Health and Protega Pharmaceuticals addresses the ongoing opioid crisis by focusing on abuse-deterrent formulations and responsible dispensing practices. This aligns with industry trends towards safer pain management solutions and regulatory compliance.

Comparison to Industry Standards

• The collaboration between Wellgistics and Protega is similar to other partnerships between pharmaceutical distributors and manufacturers to promote responsible opioid prescribing and dispensing.
• Companies like Cardinal Health, McKesson, and AmerisourceBergen have implemented programs to combat opioid abuse and diversion.
• The focus on abuse-deterrent formulations aligns with the FDA's efforts to encourage the development and use of safer opioid products.
• The collaboration's emphasis on pharmacist education is consistent with industry best practices for responsible opioid management.

Management Changes

Related Party Transactions

• The Company entered into that certain Membership Interest Purchase Agreement dated May 11, 2023, as amended, by and among Wellgistics Health, Wellgistics LLC, Strategix Global LLC, Nomad Capital LLC, Jouska Holdings LLC, and Brian Norton, governing the acquisition by the Company of Wellgistics LLC (the Wellgistics MIPA).
• At the time of entering the Wellgistics MIPA, Mr. Norton was an employee of the Company and the Chief Executive Officer of Wellgistics LLC.
• In August 2024, the Company and Wellgistics LLC, acting through Mr. Norton, consummated the transactions contemplated by the Wellgistics MIPA to revise the purchase price to be paid by the Company.

Stakeholder Impact

• Shareholders may be positively impacted by the appointment of a new CEO and the potential for increased revenue and profitability.
• Employees may benefit from the company's growth and expansion, as well as the focus on responsible business practices.
• Customers (pharmacies) will have access to educational resources and a wider range of products and services.
• Patients may benefit from safer pain management options and improved access to medications.

Next Steps

• Wellgistics LLC will distribute ROXYBOND to independent pharmacies across 50 states.
• Pharmacists will be provided with educational resources on responsible opioid dispensing and abuse-deterrent formulations.
• The companies will continue to collaborate on initiatives to support safer pain management practices.

Key Dates